<DOC>
	<DOCNO>NCT00354536</DOCNO>
	<brief_summary>This study placebo-controlled study patient Type 2 Diabetes Mellitus ass safety tolerability parameter , level GSK716155 bloodstream give dose 7 day apart , impact medication various substance blood . Assessments include ECGs , vital sign , repeat blood sample monitoring side effect .</brief_summary>
	<brief_title>In-patient Study With GSK716155 In Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>rGLP-1 protein</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Inclusion criterion : Subjects must type 2 diabetes mellitus diagnose least three month . Must take either ( 1 ) medication diabetes ( 2 ) take metformin , sulfonylurea , metformin sulfonylurea . Subjects must willing washout medication 14 day prior start study . Subjects must BMII 25 40 kg/mÂ² weigh leas 50kg . Women must nonchildbearing potential . Exclusion criterion : Laboratory value meet certain criterion ( example , total cholesterol &gt; 240 mg/dL ) . Clinically significant hepatic enzyme elevation . Fasting plasma glucose great 240mg/dL . Positive test result Hepatitis B surface antigen , positive Hepatitis C HIV . Any major illness diabetes . Previous use insulin treatment diabetes . Significant renal disease define screen lab test . History drug allergy , opinion investigator contradicts subject participation . Smoking use nicotinecontaining product within previous 6 month . History alcohol drug abuse . Unwilling abstain alcohol study . Unwilling abstain caffeine xanthinecontaining product study . Use St. John 's Wort study . Has donate 500 nL blood within 56 day dose plan donate blood month follow study participation . Previously receive GLP1 mimetic moe 70 % sequence homology GLP1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>GSK716155</keyword>
	<keyword>albiglutide</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>